Background Phase III trials of long-acting injectable (LAI) PrEP, currently underway, have great potential for expanding the menu of HIV prevention options. Imagining a future in which multiple PrEP modalities are available to potential users of biomedical HIV prevention, we investigated which factors might help direct a patient-physician shared-decision making process to optimize the choice of biomedical HIV prevention method. Methods Participants (n = 105; ages 19–63; 46.7% men of color) were former participants in a PrEP demonstration project and had taken daily oral PrEP for ≥ 12 months. Participants were given information about LAI PrEP and asked whether they would be interested in switching from oral to LAI PrEP. Participants were al...
INTRODUCTION: Despite healthcare providers\u27 growing awareness of pre-exposure prophylaxis (PrEP),...
People who inject drugs (PWID) have extraordinarily low uptake of human immunodeficiency virus (HIV)...
Abstract New forms of HIV pre-exposure prophylaxis (PrEP) include long-acting injectables and topica...
Background: Phase III trials of long-acting injectable (LAI) PrEP, currently underway, have great po...
BACKGROUND:Phase III trials of long-acting injectable (LAI) PrEP, currently underway, have great pot...
Objectives: We sought to determine preferences for oral versus long-acting injectable (LAI) PrEP amo...
Clinical trials are currently investigating the safety and efficacy of long-acting injectable (LAI) ...
Objectives Clinical trials are currently investigating the safety and efficacy of long-acting injec...
In the context of continued high rates of condomless anal intercourse and HIV-1 infection, young men...
PURPOSE: For gay and bisexual men (GBM), research suggests that familiarity with Pre-Exposure Prophy...
In the context of continued high rates of condomless anal intercourse and HIV-1 infection, young men...
Background: Optimising HIV pre-exposure prophylaxis (PrEP) provision requires insight into preferenc...
BACKGROUND: The use of antiviral medications by HIV negative people to prevent acquisition of HIV or...
Once-daily Truvada (Emtricitabine/Tenofovir) as a method of pre-exposure prophylaxis (PrEP) is one o...
The purpose of this dissertation was to: 1) estimate willingness to use PrEP (WTUP) among men who ha...
INTRODUCTION: Despite healthcare providers\u27 growing awareness of pre-exposure prophylaxis (PrEP),...
People who inject drugs (PWID) have extraordinarily low uptake of human immunodeficiency virus (HIV)...
Abstract New forms of HIV pre-exposure prophylaxis (PrEP) include long-acting injectables and topica...
Background: Phase III trials of long-acting injectable (LAI) PrEP, currently underway, have great po...
BACKGROUND:Phase III trials of long-acting injectable (LAI) PrEP, currently underway, have great pot...
Objectives: We sought to determine preferences for oral versus long-acting injectable (LAI) PrEP amo...
Clinical trials are currently investigating the safety and efficacy of long-acting injectable (LAI) ...
Objectives Clinical trials are currently investigating the safety and efficacy of long-acting injec...
In the context of continued high rates of condomless anal intercourse and HIV-1 infection, young men...
PURPOSE: For gay and bisexual men (GBM), research suggests that familiarity with Pre-Exposure Prophy...
In the context of continued high rates of condomless anal intercourse and HIV-1 infection, young men...
Background: Optimising HIV pre-exposure prophylaxis (PrEP) provision requires insight into preferenc...
BACKGROUND: The use of antiviral medications by HIV negative people to prevent acquisition of HIV or...
Once-daily Truvada (Emtricitabine/Tenofovir) as a method of pre-exposure prophylaxis (PrEP) is one o...
The purpose of this dissertation was to: 1) estimate willingness to use PrEP (WTUP) among men who ha...
INTRODUCTION: Despite healthcare providers\u27 growing awareness of pre-exposure prophylaxis (PrEP),...
People who inject drugs (PWID) have extraordinarily low uptake of human immunodeficiency virus (HIV)...
Abstract New forms of HIV pre-exposure prophylaxis (PrEP) include long-acting injectables and topica...